Frederic Dumais - Valeo Pharma Director Relations

All Insiders . USA . 
Stock . Valeo Pharma . Stakeholders . Insider . Frederic Dumais
VPHIF Stock  USD 0.05  0.07  60.92%   

Insider

Frederic Dumais is Director Relations of Valeo Pharma
Phone514 694 0150
Webhttps://www.valeopharma.com

Valeo Pharma Management Efficiency

The company has return on total asset (ROA) of (0.2648) % which means that it has lost $0.2648 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (16.0041) %, meaning that it generated substantial loss on money invested by shareholders. Valeo Pharma's management efficiency ratios could be used to measure how well Valeo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Valeo Pharma has accumulated 59.53 M in total debt. Valeo Pharma has a current ratio of 2.82, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Valeo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Valeo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Valeo Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Valeo to invest in growth at high rates of return. When we think about Valeo Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Tejinder VirkAkanda Corp
42
OriMoni MimonINC Research Holdings
36
Elizabeth JDANI Pharmaceuticals
N/A
Kevin MacDermottcbdMD Inc
62
David EricksonEvolus Inc
N/A
Scott SudduthCollegium Pharmaceutical
N/A
Advocate OhayonINC Research Holdings
35
Rami LevyINC Research Holdings
59
Raymond CoffmancbdMD Inc
62
Hermann LubbertBiofrontera
68
Marlo ManningCollegium Pharmaceutical
N/A
Jeff HolmBiofrontera
N/A
Muthusamy RPhANI Pharmaceuticals
56
BComm BComAkanda Corp
68
BCom BAccAkanda Corp
44
Erica CPABiofrontera
39
Thomas FlowAkanda Corp
46
Mark BaldygaBiofrontera
N/A
Sibyl SwiftcbdMD Inc
43
John WestoncbdMD Inc
N/A
Amos CohenINC Research Holdings
45
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. The company was incorporated in 2003 and is headquartered in Kirkland, Canada. Valeo Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 100 people. Valeo Pharma [VPHIF] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

Return On Equity-16.0
Return On Asset-0.26

Valeo Pharma Leadership Team

Elected by the shareholders, the Valeo Pharma's board of directors comprises two types of representatives: Valeo Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valeo. The board's role is to monitor Valeo Pharma's management team and ensure that shareholders' interests are well served. Valeo Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valeo Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jean Fournier, Head Unit
Steven CA, Vice CEO
Kyle Steiger, VP Officer
MBA MBA, VP CFO
GuyPaul Allard, VP Sec
Frederic Dumais, Director Relations

Valeo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Valeo Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-16.0
Return On Asset-0.26
Profit Margin(0.93) %
Operating Margin(0.61) %
Current Valuation57.28 M
Shares Outstanding82.19 M
Shares Owned By Insiders47.72 %
Price To Book66.75 X
Price To Sales2.14 X
Revenue27.75 M

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Valeo Pink Sheet

Valeo Pharma financial ratios help investors to determine whether Valeo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valeo with respect to the benefits of owning Valeo Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY